drugset / Trial / NCT00293098

Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease

NCT00293098

Expanded access Approved for marketing Children's Hospital of Philadelphia ApoPharma · collab

Summary

Patients who have iron overload due to chronic blood transfusions and have developed heart failure or who are at high risk of heart failure because of the high levels of iron in their hearts, will be treated with deferiprone, an investigational drug, in combination with deferoxamine (Desferal). Some studies suggest that deferiprone may be better than deferoxamine in removing iron from the heart and improving heart function, and that using both drugs together may remove more iron. Participants would make a clinic visit for lab studies each week, and would continue to take deferiprone for as long as their physician feels it is useful in their care.

Timeline

Start
2006-03
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferiprone Small molecule 75 mg/kg Oral